Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.47 |
| ▸ | CDK2 | P24941 | 13/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373572 | 0.94 | IGF1R (0.51) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL1372698 | 0.89 | IGF1R (0.53) | IGF1RCCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL1370364 | 0.89 | IGF1R (0.56) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL1371421 | 0.89 | IGF1R (0.69) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL4284393 | 0.87 | IGF1R (0.54) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL4284385 | 0.87 | IGF1R (0.53) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL1371453 | 0.87 | IGF1R (0.52) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL1374085 | 0.86 | INSR (0.61) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL1370806 | 0.86 | IGF1R (0.61) | IGF1RCCNA2CDK2CCNA1INSR | |
| SCHEMBL1370760 | 0.85 | IGF1R (0.49) | IGF1RCCNA2CDK2CCNA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885CCNA2 1504/4885CDK2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.